The short answer
Retatrutide was described by Coskun and colleagues in Cell Metabolism in September 2022. Phase 2 results appeared in the New England Journal of Medicine in 2023, and the Phase 3 TRIUMPH programme reported from December 2025 through July 2026, with an FDA filing signalled for Q1 2027.
Key facts
- Discovery paper
- Coskun, Cell Metab, Sept 2022
- Phase 2
- Jastreboff, NEJM 2023 (PMID 37366315)
- Phase 2 in T2D
- Rosenstock, Lancet 2023 (PMID 37385280)
- First Phase 3 readout
- TRIUMPH-4, December 2025
- Pivotal readout
- TRIUMPH-1, 21 May 2026
- Signalled FDA filing
- Q1 2027
- Approvals
- None, anywhere
The discovery paper
Coskun and colleagues published LY3437943's discovery and characterisation in Cell Metabolism in September 2022, subtitled from discovery to clinical proof of concept. It describes the design objective (balanced agonism across GIP, GLP-1 and glucagon receptors) and the pharmacology achieved. It remains the primary structural reference.
Phase 2 and the numbers that drew attention
Jastreboff and colleagues reported the Phase 2 obesity trial in the New England Journal of Medicine in 2023, and Rosenstock and colleagues reported in adults with type 2 diabetes in the Lancet the same year. The obesity figures were the largest then reported for any single-molecule incretin agonist, which is what made retatrutide the compound the field watched.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The Phase 3 programme
TRIUMPH enrolled more than 5,800 participants. TRIUMPH-4 reported first in December 2025. TRIUMPH-1, the pivotal obesity study, reported on 21 May 2026. TRIUMPH-2 and TRIUMPH-3 followed in July 2026, covering type 2 diabetes and established cardiovascular disease. All met their primary endpoints.
Where it stands now
Investigational everywhere. Lilly has signalled a Biologics License Application to the FDA in the first quarter of 2027, and no MHRA or EMA timeline has been announced. Further readouts including maintenance-dosing studies remain outstanding; TRIUMPH-6 has a primary completion date of April 2028.
A citation worth getting right
The two Phase 2 papers are frequently miscited. Jastreboff's NEJM paper is PMID 37366315 and Rosenstock's Lancet paper is PMID 37385280. This library previously carried neighbouring PMIDs that resolved to a paediatric ophthalmology paper and a cardiothoracic surgery commentary. They were corrected earlier this week, and are a reasonable illustration of how easily a plausible-looking identifier goes wrong.
Frequently asked questions
When was retatrutide first described?
Coskun and colleagues published its discovery in Cell Metabolism in September 2022.
Has it been approved anywhere?
No. It remains investigational in every jurisdiction, with an FDA filing signalled for Q1 2027.
What is still outstanding?
Maintenance-dosing data. TRIUMPH-6 has a primary completion date of April 2028.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al., LY3437943. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide in type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov: TRIUMPH-6 (NCT06859268)clinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- Retatrutide Clinical Trial Timeline: Phase 1 to TRIUMPHRetatrutide trial timeline: Phase 1 in 2020, Phase 2 in NEJM 2023, Phase 3 TRIUMPH readouts December 2025 to July 2026, FDA filing signalled for Q1 2027.
- Who Develops Retatrutide?Eli Lilly, under the code LY3437943. Why that matters for reading trial data, and why no licensed retatrutide product exists.
- Retatrutide Half-Life: Where It Comes FromThe C20 diacid binds albumin reversibly, supporting once-weekly trial dosing. Why chain length sets duration across the whole incretin family.
- Retatrutide Chemical Identity: What Can Actually Be VerifiedRetatrutide has no findable PubChem record. What that means for its reported CAS and molecular weight, and why one widely cited identifier is tirzepatide's.
- How the Incretin Field Got HereExenatide from lizard venom, liraglutide's fatty acid, semaglutide's weekly dosing, then multi-agonism. Each generation solved the previous one's limit.